In a mid-stage study, the candidate itolizumab achieved 23.3% clinical remission rate at 12 weeks, numerically better than ...

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to ...

Equillium and Biocon announce positive data from phase 2 study of itolizumab to treat moderate to severe ulcerative colitis: Our Bureau, Bengaluru Friday, February 7, 2025, 10:30 ...

If you are taking a JAK inhibitor for moderate to severe UC symptoms, your healthcare professional will likely recommend one of the following: There are several treatments for ulcerative colitis ...

Ulcerative colitis (UC) is a form of inflammatory bowel ... The authors state that moderate-intensity exercise may be safe and potentially beneficial for people whose symptoms are not severe.

PORTLAND, OR, UNITED STATES, February 7, 2025 /EINPresswire / -- The global ulcerative colitis (UC) market is ex ...

Equillium (EQ) and Biocon announced topline results from the Phase 2 study evaluating itolizumab in the treatment of moderate to severe ...

The composite of patient-reported clinical response and endoscopic response was significantly greater in mirikizumab versus ...

Bengaluru: Equillium, Inc., a clinical-stage biotechnology company and Biocon Limited, an innovation-led global ...